Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1986 May;53(5):601–606. doi: 10.1038/bjc.1986.102

Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.

I R Judson, C J Rutty, G Abel, M A Graham
PMCID: PMC2001385  PMID: 3087399

Abstract

Trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine) is an analogue of pentamethylmelamine (PMM). In early clinical trials PMM failed to show significant anti-tumour activity in man which was attributed to poor metabolic activation. Trimelamol does not require activation and is therefore expected to be more active in man. PMM caused dose-limiting emesis and sedation whereas Trimelamol is much less neurotoxic in rodents. The relative penetration of PMM and Trimelamol into mouse brain has therefore been examined. Mice receiving PMM at 90 mg kg-1 i.p. were found to have high concentrations of the drug in the CNS compared to plasma (mean brain/plasma ratio 1.04) whereas animals receiving Trimelamol had consistently low CNS concentrations (mean brain/plasma ratio 0.08). This difference did not correlate with plasma protein binding which is greater for PMM (68.2%) than for Trimelamol (17.5%). However, it does appear to be related to lipophilicity. In Phase I clinical trial Trimelamol has proved much less emetic than PMM and causes no acute sedation. It is likely that this reduction in toxicity may be explained by the relatively poor ability of Trimelamol to enter the CNS.

Full text

PDF
601

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azmin M. N., Stuart J. F., Florence A. T. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol. 1985;14(3):238–242. doi: 10.1007/BF00258124. [DOI] [PubMed] [Google Scholar]
  2. Blum R. H., Livingston R. B., Carter S. K. Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer. 1973 Mar;9(3):195–202. doi: 10.1016/s0014-2964(73)80019-2. [DOI] [PubMed] [Google Scholar]
  3. Casper E. S., Gralla R. J., Lynch G. R., Jones B. R., Woodcock T. M., Gordon C., Kelsen D. P., Young C. W. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion. Cancer Res. 1981 Apr;41(4):1402–1406. [PubMed] [Google Scholar]
  4. Cumber A. J., Ross W. C. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chem Biol Interact. 1977 Jun;17(3):349–357. doi: 10.1016/0009-2797(77)90097-7. [DOI] [PubMed] [Google Scholar]
  5. Goldberg R. S., Griffin J. P., McSherry J. W., Krakoff I. H. Phase I study of pentamethylmelamine. Cancer Treat Rep. 1980;64(12):1319–1322. [PubMed] [Google Scholar]
  6. Ihde D. C., Dutcher J. S., Young R. C., Cordes R. S., Barlock A. L., Hubbard S. M., Jones R. B., Boyd M. R. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):755–762. [PubMed] [Google Scholar]
  7. Legha S. S., Slavik M., Carter S. K. Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer. 1976 Jul;38(1):27–35. doi: 10.1002/1097-0142(197607)38:1<27::aid-cncr2820380106>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  8. Muindi J. R., Newell D. R., Smith I. E., Harrap K. R. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. Br J Cancer. 1983 Jan;47(1):27–33. doi: 10.1038/bjc.1983.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rutty C. J., Abel G. In vitro cytotoxicity of the methylmelamines. Chem Biol Interact. 1980 Feb;29(2):235–246. doi: 10.1016/0009-2797(80)90036-8. [DOI] [PubMed] [Google Scholar]
  10. Rutty C. J., Connors T. A. In vitro studies with hexamethylmelamine. Biochem Pharmacol. 1977 Dec 15;26(24):2385–2391. doi: 10.1016/0006-2952(77)90446-4. [DOI] [PubMed] [Google Scholar]
  11. Rutty C. J., Newell D. R., Muindi J. R., Harrap K. R. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. Cancer Chemother Pharmacol. 1982;8(1):105–111. doi: 10.1007/BF00292880. [DOI] [PubMed] [Google Scholar]
  12. Stewart D. J., Benvenuto J. A., Leavens M., Smith R. G., Cabanillas F., Benjamin R. S., Loo T. L. Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neurooncol. 1983;1(4):357–364. doi: 10.1007/BF00165719. [DOI] [PubMed] [Google Scholar]
  13. Van Echo D. A., Chiuten D. F., Whitacre M., Aisner J., Lichtenfeld J. L., Wiernik P. H. Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Cancer Treat Rep. 1980;64(12):1335–1339. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES